The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

Market OverviewThe Global Monoclonal Antibodies Market has experienced significant growth over the past few decades, driven ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Conducted by leading digital insights consultancy Creation Healthcare, the research identified more than 80,000 posts on X (formerly Twitter) referencing prostate cancer, generated by more than 17,000 ...

DelveInsight's HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, HPV16+ HNSCC emerging drugs, market ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.